



The Belgian Society for Toxicology and Ecotoxicology

5th Workshop on Non-Clinical Safety Assessment of Biopharmaceuticals

“The importance of species selection to predict the human safety of biopharmaceuticals ”

Thursday 11 May 2017

Janssen Pharmaceuticals, Beerse, Belgium

Programme

8:30 – 9:00	Coffee	
9:00 – 9:10	Welcome	M. Cornet, President of BelToX
Morning session: Lectures		
9:10 – 9:40	Species selection for the non-clinical testing of Biologicals I. Andreini, RTC, Italy	
9:40 – 10:10	Importance of the nonhuman primate in the assessment of Biologicals S. Grote-Wessels, Covance Munster, Germany	
10:10 – 10:40	Coffee break and networking	
10:40 – 12:20	Examples	
	10:40-11:05	Alternative approaches to preclinical safety assessment when you have no standard tox species S. Marshall, Envigo, UK
	11:05-11:30	Contribution of immunohistochemistry and tissue cross reactivity to species selection F. Gervais, CitoxLab, France
	11:30-11:55	Are effects in non-clinical species translating into humans ? A. Cauvin, UCB Biopharma, Belgium
	11:55-12:20	Animal models to evaluate vaccine-induced enhanced disease in RSV and other infectious diseases R. Zahn, J&J, The Netherlands
	12:20-12:40	Panel discussion
12:40 – 13:45	Lunch and networking	
Afternoon session: Case studies analysis		
13:45 – 13:55	Introduction to breakout sessions	
13:55 – 15:00	Breakout sessions	
15:00 – 15:30	Coffee break and networking	
15:30 – 16:30	Case study reporting and discussion	
16:30 – 16:40	Concluding remarks	

Organizing Committee: Annick Cauvin and Miranda Cornet (UCB Biopharma), Judith Baumeister and Frédérique Delannois (GSK Vaccines), Miek Desmidt, Ad Knaapen and Kristel Steemans (Johnson & Johnson), Andreas Hohlbaum (Abylnx),

Info and registration : www.beltox.be